← back to search

Xiaolan Chen

Nantong University · CN
Area of research
Nephrology · Pulmonary and Respiratory Medicine
Research interest
Research focused on Fibrosis and Microvesicles, with related work in Renal cell carcinoma, Macrophage polarization, Univariate analysis. Notable publications include 'Exosomes from tubular epithelial cells undergoing epithelial‐to‐mesenchymal transition promote renal fibrosis by M1 macrophage activation', 'The Prognostic Assessment of CDC20 in Patients with Renal Clear Cell Carcinoma and Its Relationship with Body Immunity', and 'Identification of biomarkers for chronic renal fibrosis and their relationship with immune infiltration and cell death'.
h-index
citations
33
works
3
NIH funding
primary concept
email

Recent publications

Identification of biomarkers for chronic renal fibrosis and their relationship with immune infiltration and cell death
Renal Failure 2025cited by 6position: lastdoi
Exosomes from tubular epithelial cells undergoing epithelial‐to‐mesenchymal transition promote renal fibrosis by <scp>M1</scp> macrophage activation
FASEB BioAdvances 2023cited by 17position: lastdoi
The Prognostic Assessment of CDC20 in Patients with Renal Clear Cell Carcinoma and Its Relationship with Body Immunity
Contrast Media & Molecular Imaging 2022cited by 10position: lastdoi

Grants

No grants ingested yet.

Frequent collaborators

Yinhao Chen · Nantong University2 papers (2022–2025)Xuerong Wang · Anhui Medical University2 papers (2022–2023)Xiameng Gu · Nantong University2 papers (2022–2023)Hao Shen · Nantong University1 papers (2025–2025)Jing Liu · First Affiliated Hospital of Guangzhou Medical University1 papers (2022–2022)Rui Zhang · University of Minnesota1 papers (2023–2023)Rong Wang · Nantong University1 papers (2025–2025)Peipei Xi · Nantong University1 papers (2023–2023)Haonan Sha · Ningbo University1 papers (2025–2025)Xinyue Qin · Nantong University1 papers (2025–2025)Yuqing Lu · Nantong University1 papers (2023–2023)Jiaqi Shi · Shanghai Jiao Tong University1 papers (2025–2025)